ProMIS Neurosciences Publishes Alzheimer's Research Findings
ProMIS Neurosciences announced a publication in the peer-reviewed journal Alzheimer's & Dementia: Translational Research & Clinical Interventions. entitled, "Relationship between efficacy and preferential targeting of soluble Abeta aggregates." Key Findings and Implications for PMN310: PMN310 showed the highest resistance to monomer competition among all antibodies tested, preserving oligomer binding while pan-Abeta antibodies lost activity in in vitro models. This suggests that a higher proportion of each dose of PMN310 could be available to reach the relevant toxic targets, which could potentially translate into clinical benefit in patients. Findings provide preclinical evidence supporting a possible reduced ARIA risk. All other antibodies tested in the study appeared to bind monomers and/or plaque to varying degrees. PMN310 was the only antibody in the study showing strict specificity for toxic soluble oligomers while avoiding monomers and plaque.
Trade with 70% Backtested Accuracy
Analyst Views on PMN
About PMN
About the author

Phoenix Mecano Valued at CHF 769, Currently 44% Undervalued
- Intrinsic Value Assessment: Utilizing a two-stage discounted cash flow model, Phoenix Mecano's intrinsic value is estimated at CHF 769, indicating a 44% undervaluation compared to its current share price of CHF 434, reflecting conservative market expectations for future cash flows.
- Future Cash Flow Forecast: The projected free cash flow is expected to grow annually, starting at €28.3 million in 2026 and reaching €57 million by 2035, indicating strong growth potential in the company's profitability and cash generation capabilities.
- Terminal Value Calculation: The estimated terminal value is €887 million, with a present value of €452 million, demonstrating the company's stable growth potential in the long term despite market volatility and industry cyclicality risks.
- Investment Risk Warning: While the company shows strong dividend performance, it has experienced a decline in earnings over the past year, and revenue growth is expected to be below 20%, necessitating investor attention to these potential risks when assessing investment value.

Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.






